bempikibart
Generic: ADX-914·Code: ADX-914
bempikibart: sourced relationships with 1 company · 1 clinical trial tracked.
bempikibart evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect bempikibart to QTTB; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could bempikibart → QTTB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Q32 Bio Inc. (QTTB) | Phase 2 |
Clinical Trial Registry Records (1)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Primary endpoint: Part A: Mean relative percent change in SALT score
Interventionalopen75 targetStarted 2023-09Completion 2026-0933 sites · Canada, United StatesQ32 Bio Inc.
Frequently asked questions
Which companies have sourced relationships with bempikibart?
bempikibart has dated SEC/FDA relationship records for Q32 Bio Inc..
How many clinical trials involve bempikibart?
BioSniper tracks 1 clinical trial involving bempikibart.